About IMUNON
IMUNON is a company based in Lawrenceville (United States) founded in 1982. The company has 25 employees as of December 31, 2024. IMUNON offers products and services including DNA-based Therapies and Nucleic Acid Vaccines. IMUNON operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Lawrenceville, United States
- Employees 25 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Imunon, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$18.62 M (USD)4.58as on Dec 31, 2024
-
EBITDA
-$18.41 M (USD)9.34as on Dec 31, 2024
-
Latest Funding Round
$3.25 M (USD), Post-IPO
May 23, 2025
- Investors
-
Employee Count
25
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of IMUNON
IMUNON is a publicly listed company on the NASDAQ with ticker symbol IMNN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of IMUNON
IMUNON offers a comprehensive portfolio of products and services, including DNA-based Therapies and Nucleic Acid Vaccines.
Treats cancer using proprietary DNA platforms for immune enhancement.
Targets infectious diseases and cancer via DNA-based immune responses.
Funding Insights of IMUNON
Investors in IMUNON
IMUNON has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for IMUNON
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IMUNON
Investment portfolio details for IMUNON
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IMUNON
Detailed financials for IMUNON
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Imunon Comparisons
Peer comparison for IMUNON
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IMUNON
IMUNON operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of IMUNON
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Imunon
Complete news archive for IMUNON
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IMUNON
IMUNON was founded in 1982 and raised its 1st funding round 28 years after it was founded.
IMUNON is headquartered in Lawrenceville, United States.
Corinne Le Goff is the current CEO of IMUNON.
As of Dec 31, 2024, the latest employee count at IMUNON is 25.
IMUNON was founded in 1982 and is based in Lawrenceville, United States, within the biotechnology sector. Focus is placed on developing immunotherapeutics for cancer, including the lead candidate GEN-1, a DNA-based immunotherapy targeted at ovarian cancer. The TheraPlas platform supports nucleic acid-based anti-cancer therapies, and the PLACCINE platform enables nucleic acid vaccines for infectious diseases and cancer applications. Operations emphasize research and development in these areas.
IMUNON's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
IMUNON offers DNA-based Therapies and Nucleic Acid Vaccines.
Yes, IMUNON is publicly traded on NASDAQ under the ticker symbol IMNN.
IMUNON has 1 investor. Key investors include HHS.
The ticker symbol of IMUNON is IMNN on NASDAQ.